Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Feb;40(2):406-411.
doi: 10.1007/s10875-019-00729-x. Epub 2020 Jan 2.

A Novel, Heterozygous Three Base-Pair Deletion in CARD11 Results in B Cell Expansion with NF-κB and T Cell Anergy Disease

Affiliations
Case Reports

A Novel, Heterozygous Three Base-Pair Deletion in CARD11 Results in B Cell Expansion with NF-κB and T Cell Anergy Disease

Adrian M Shields et al. J Clin Immunol. 2020 Feb.

Abstract

Germline gain-of-function mutations in CARD11 lead to the primary immunodeficiency, B cell expansion with NF-κB, and T cell anergy (BENTA). Herein, we report the case of a girl, presenting at 2 years of age with lymphocytosis and splenomegaly in whom a novel, in-frame, three base pair deletion in CARD11 was identified resulting in the deletion of a single lysine residue (K215del) from the coiled-coil domain. In vitro functional assays demonstrated that this variant leads to a subtle increase in baseline NF-κB signaling and impaired proliferative responses following T cell receptor and mitogenic stimulation. Previously reported immunological defects associated with BENTA appear mild in our patient who is now 6 years of age; a B cell lymphocytosis and susceptibility to upper respiratory tract infections persist; however, she has broad, sustained responses to protein-polysaccharide conjugate vaccines and displays normal proliferative responses to ex vivo T cell stimulation.

Keywords: BENTA; CARD11; Primary immunodeficiency.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Immunity. 2003 Jun;18(6):763-75 - PubMed
    1. J Exp Med. 2012 Nov 19;209(12):2247-61 - PubMed
    1. Front Immunol. 2017 Aug 02;8:913 - PubMed
    1. J Allergy Clin Immunol. 2015 Sep;136(3):819-821.e1 - PubMed
    1. Br J Cancer. 2004 Jul 19;91(2):355-8 - PubMed

LinkOut - more resources